High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors
Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if I-131 Metaiodobenzylguanidine (MIBG)
can shrink or slow the growth of the tumor(s) in patients with metastatic neuroendocrine
tumors. The safety of this treatment will also be studied.